C07D 513/18
Bridged systems
C07D513/18 (Bridged systems) appears on 99 US grants and 123 published applications in this corpus.
Search patents in C07D- Granted patents
- 99
- Published applications
- 123
- Assignees
- 83
- Inventors
- 447
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 3 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 7 |
| 2005 | 0 | 3 |
| 2006 | 2 | 0 |
| 2007 | 1 | 0 |
| 2008 | 2 | 2 |
| 2009 | 0 | 3 |
| 2010 | 1 | 8 |
| 2011 | 2 | 6 |
| 2012 | 7 | 7 |
| 2013 | 6 | 6 |
| 2014 | 5 | 8 |
| 2015 | 6 | 4 |
| 2016 | 4 | 5 |
| 2017 | 4 | 3 |
| 2018 | 1 | 7 |
| 2019 | 6 | 5 |
| 2020 | 7 | 6 |
| 2021 | 3 | 8 |
| 2022 | 4 | 3 |
| 2023 | 4 | 11 |
| 2024 | 6 | 8 |
| 2025 | 2 | 3 |
| 2026 | 5 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Macrocyclic compounds, compositions, and methods of using thereof9 Jun 2026US 12,649,750 B2Genzyme Corporation
- Use of H3K9me3 modulation for enhancing cognitive function12 May 2026US 12,622,916 B2
- Macrocyclic compounds, compositions, and methods of using thereof12 May 2026US 12,624,051 B2Genzyme Corporation
- Heat shock protein modulators and anti-Huntington disease therapeutic agents14 Apr 2026US 12,600,705 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Macrocyclic LRRK2 kinase inhibitors10 Feb 2026US 12,545,689 B2Oncodesign Precision Medicine
- Ras inhibitors1 Oct 2026US 2026/0297112 A1Revolution Medicines, Inc.
- Use of h3k9me3 modulation for enhancing cognitive function13 Aug 2026US 2026/0232688 A1The Regents of the University of California
- Nlrp3 modulators16 Jul 2026US 2026/0200935 A1Zomagen Biosciences Ltd
- 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer21 May 2026US 2026/0137703 A1Cancer Research Technology Limited
- Ras inhibitors19 Mar 2026US 2026/0078133 A1Revolution Medicines, Inc.
Most cited
By later US patents
- Macrocyclic derivatives for the treatment of diseases40US 8,680,111 B2Pfizer Inc. · 2014
- Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof35US 5,569,655 ASterling Winthrop Inc. · 1996
- Macrocyclics pyrimidines as aurora kinase inhibitors18US 8,815,872 B2Merck Patent GmbH · 2014
- Macrocyclic derivatives for the treatment of diseases14US 9,133,215 B2Pfizer Inc. · 2015
- Macrocyclic integrase inhibitors13US 8,497,270 B2Elanco Animal Health Ireland Limited · 2013